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Abstract
Non-invasive ventilation ( NIV ) has been used successfully for the management of acute respiratory failure (ARF) more often in 
the last two decades than previously. Unfortunately, NIV can have failure rates ranging from 5% to 50% and patient selection is 
the key to success. There are particular groups of patients that are more likely to benefit from NIV. For patients with hypoven-
tilation syndrome (OHS) this treatment can be beneficial. This review seeks to evaluate the effectiveness of NIV in acute ARF 
and determine predictors of NIV failure in morbidly obese patients. Only a few studies have investigated NIV success or failure 
in these patients. NIV was most often effective when patients were carefully selected. Obese patients who exhibited early NIV 
failure had a high severity score at admission. In contrast, more than half of hypercapnic patients with decompensated OHS 
exhibited a delayed but successful response to NIV. Patients with decompensation of OHS had better prognosis and response to 
NIV than other hypercapnic patients. They required more aggressive NIV settings, a longer time to reduce paCO2 levels, and more 
frequently a delayed but successful response to NIV which should encourage the use of NIV rather than early intubation. Since 
clear predictors of NIV failure have not been identified, a strict and prolonged monitoring is mandatory. 
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Introduction
Patients who are likely to benefit from non in-
vasive ventilation (NIV) need to be identified early 
[1, 2]. Failure to do so often results in increased 
morbidity and mortality, as well as inappropri-
ate use of limited resources [3]. Before starting 
NIV, it is crucial to identify good candidates [1]. 
Non-invasive ventilation efficacy depends on 
careful patient selection:look for predictors of 
failure immediately [3–5]. The absence of total 
alertness and/or an inability to follow instructions 
are absolute criteria for exclusion. Hypotension, 
pneumothorax, gastric insufflation, and vomiting, 
and risk of aspiration must be evaluated; these 
are relative exclusion criteria. Clinical experience 
of all persons that form the therapeutic team are 
vital; changes in patient condition occurs rapidly. 
The risk of NIV failure determines the intensity 
of monitoring needed [6, 7]. Moreover, knowing 
the factors affecting the NIV success may help 
to decide also the duration of NIV trial. One ap-
proach to determine the need for monitoring is 
to assess the patient’s risk of NIV failure [7, 8]. 
Some of these are simple bedside assessments, 
such as ease of arousal, agitation, cough integ-
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rity, and respiratory rate. Other methods require 
simple laboratory tests, such as determination of 
arterial blood gases (ABG). Other methods require 
proven evaluation protocols: Acute Physiology 
and Chronic Health Evaluation (APACHE) II or 
Simplified Acute Physiology Score (SAPS) II. 
When a quick decision is required, reliance on 
simple bedside observations and rapidly obtained 
laboratory values such as pH are best [8]. Recogni-
tion that NIV is failing is an important, but often 
overlooked, part of clinical management [5, 6]. 
A patient with multiple risk factors for NIV failure 
should be placed in a closely monitored setting 
such as an ICU or a step-down respiratory unit. 
Three critical periods for detecting NIV failure 
have been defined: 
1)  immediate failure (within minutes to < 1 h) 
2)  early failure (1 to 48 h), and 
3)  late failure (after 48 h) [5–9]. 
Immediate NIV failure
Immediate NIV failure refers to failure with-
in sixty minutes [9]. Predictors of failure in this 
period have never been systematically analyzed. 
A weak cough reflex leading to inefficient clear-
ance of excessive secretions from airways is 
a common cause of immediate NIV failure. The 
inability to spontaneously remove secretions is 
considered a contraindication to NIV, e. g. , pa-
tients with impaired consciousness and depressed 
cough reflex. Hypercapnic encephalopathy (HES) 
has been often considered a cause of immediate 
NIV failure because of poor compliance due to 
confusion and/or agitation. It is a  relative con-
traindication because of the increased risk of 
aspiration [6, 8]. The risk of aspiration has been 
shown to be minimized by the rapid improvement 
of neurological status. Patient tolerance has been 
shown to be critical for NIV success, especially 
in the first few minutes while the patient adapts 
to this “new mode” of breathing [9]. 
Early NIV failure 
Nearly 65% of NIV failures occur within the 
first 48 hours of NIV use [9–11]. This time interval 
has received more attention in assessments of NIV 
failure than any other. Several investigators have 
tried to assess the best predictors of NIV failure. 
Confalonieri et al. [7] found that subjects likely 
to fail NIV had more severe respiratory acidosis, 
a lower level of consciousness, were older, more 
hypoxemic, and/or had a higher respiratory rate 
on presentation. Clinical signs that are only 
equivocal on presentation become more defini-
tively predictive of failure if they persist after 2 h 
of NIV. It is important to assess clinical trajectory 
during the first two hours of NIV. Subjects who 
have a pH < 7.25, an APACHE II score > 29, and 
a Glasgow coma score < 11 on presentation to 
the hospital have failure rates ranging from 64% 
to 82% are at risk for early failure. Moreover, 
patients with excessive respiratory secretions or 
without improvement of clinical and/or after 60 
minutes of NIV have high risk of failure [12–14]. 
Late NIV failure
Late NIV failure (after 48 h) is an event 
occurring after an initial good response to NIV. 
It is more likely in subjects who, at the time of ad-
mission, showed functional limitations evaluated 
using a score correlated to activities of daily living 
(ADL), a higher number of comorbidities (such 
as renal failure, chronic heart failure, diabetes ), 
a lower pH at baseline, and the underlying cause 
of acute respiratory failure (ARF), e. g., pneumo-
nia [12, 14–18]. 
NIV is being increasingly used for the man-
agement of acute and chronic respiratory failure. 
Over the past two decades, increasing evidence 
has established its place as the first line therapy 
for certain forms of ARF [1], particularly those 
resulting from acute exacerbations of chronic 
obstructive pulmonary disease (COPD), and 
cardiogenic pulmonary [1, 2]. Its usefulness has 
also been confirmed in patients who are immuno- 
-compromised from hematological diseases in 
which lower rates of endotracheal intubation and 
mortality rates have been reported in comparison 
with more invasive therapy [15]. Over the time, 
NIV was used in more severe patients and sever-
al clinical situations with proven efficacy (e. g. 
restrictive lung diseases, obesity hypoventilation 
syndrome (OHS) and weaning from invasive 
mechanical ventilation) [6]. Since NIV can have 
failure rates ranging from 5% to 50%, NIV failure 
may cause intubation delay, increasing morbidity 
and mortality [11, 12]. 
More than 30% of patients with OHS are 
diagnosed initially when hospitalized for acute 
on chronic respiratory failure [16–18]. Patients 
with OHS often respond well to NIV. The patho-
physiology of OHS results from complex inter-
actions between various sleep breathing disor-
ders (obstructive sleep apnea, reduced REM, 
sleep hypoventilation) [19], increased work of 
breathing due to decreased thoraco-abdominal 
compliance, and altered ventilatory drive [20]. 
Respiratory system compliance in obese subjects 
can be reduced by the restrictive effect of fat on 
the chest wall, a tendency to breathe at low lung 
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volumes and/or fat distribution that contributes 
to high pleural pressures. This last factor leads to 
low end-expiratory volume with flow limitation 
in the supine patient [21]. 
Obesity increases the stiffness of the total 
respiratory system with consequent development 
of low lung volume [21]. Breathing at low volumes 
increases airway resistance with expiratory flow 
limitation and gas trapping due to early airway 
closure and subsequent generation of intrinsic 
positive end-expiratory pressure and ventilation 
mismatching especially in supine position and 
during sleep [20, 21]. These mechanisms can be 
successfully corrected by NIV. Patients with OHS 
can be treated in an acute care setting with better 
results than other diseases such as COPD. NIV 
reduces the respiratory load, increases minute 
volume for a given breathing effort and provides 
ventilation during central apnea episodes [21]. 
This review seeks to determine which obese 
patients are good candidates, which patients are 
poor candidates, and how to gauge the success 
(or failure) of NIV rapidly. In this reviews we 
will address three main issues: 1) evaluation the 
effectiveness of NIV in ARF 2) calibration of ven-
tilatory settings and selection modes 3) evaluation 
of predictors of NIV failure. 
Methods 
The diagnosis and the definition of severity of 
obesity has been determined by body mass index 
(BMI), defined as weight in kilograms divided by 
height in squared meters (kg/m2) [22]. Subjects 
with BMI greater than 30 are considered obese. 
Obese is further categorized into class I ( BMI 30.0– 
–34. 9), class II (35. 0–39. 9) and class III (BMI ≥ 40); 
Class III is referred as severe or extreme or mor-
bid obesity. These standards have been used 
in studies exploring the relationship between 
obesity and critical care outcomes [18]. Obesi-
ty hypoventilation syndrome (OHS) is defined 
as a combination of obesity (BMI >30 kg/m2), 
daytime hypercapnia, PaCO2 > 45 mm Hg, and 
disordered breathing during sleep [23]. OHS is 
a chronic disease associated with respiratory and 
cardio-metabolic impairments leading to a decre-
ase in ability to perform normal human activities 
including social interactions along with a higher 
risk of hospitalization and death [16, 21]. 
Data source 
We searched the following electronic data-
bases from their inception from January 2001 to 
December 2016: MEDLINE, EMBASE, CINHAIL, 
CENTRAL (Cochrane Central register of Controled 
Trials), DARE (Database of Abstracts of Reviews 
of Effectiveness), the Cochrane Database of Sy-
stamatic Reviews, ACP Journal Club database. 
Study selection
We identified studies that included adults 
admitted to acute care hospitals with acute or 
acute on chronic respiratory failure who needed 
NIV. We excluded studies of invasive mechanical 
ventilation (IMV). We included both randomized 
controlled trials and prospective studies; we 
excluded case reports, letters, and editorials. We 
have found 3738 potential articles regarding NIV 
and acute respiratory failure. 3542 were excluded 
because they did not fulfilled inclusion criteria 
(Fig. 1). For the remaining papers we read the full 
texts. Eight full-text articles were assessed for 
eligibility. No language restrictions were applied: 
non-english publications were professionally 
translated into English. 
Results
Only eight studies have investigated NIV 
success or failure in OHS patients. These are su-
mmarized in Table 1. Several observations have 
emerged from this research: 
a)  in OHS NIV failed to reversing ARF ranging 
from 2% to 60% of the time. [3, 4, 8, 10, 
24–27]. Two studies were performed in ICU 
by Lemyze et al. [10] and Contou et al. [26] 
3,716 studies 
identified and 
screened from 
database searching
22 additional 
studies identified 
from other 
sources
196 full-text articles 
assessed
184 excluded from title,
abstract, no OHS 
patients
12 full-text articles 
assessed for eligibility
4 excluded (acute 
and chronic patients)
8 full-text articles 
included
Figure 1. Study flow diagram
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Table 1. Studies which have evaluated NIV in critically ill obese patients
Ref. Year Obese  
Patients  
(n°)
Ventilator y mode NIV  
failure%
Predictors of NIV failure Mortality 
rate %
Type of sample
 [3] 2012 42 Pressure support ventilation 
(PSV ) or bilevel positive 
pressure ventilation sponta-
neous-timed (ST)
41.0% Use of home ventilation, hi-
gher pressure support levels
0% Mixed patients
 [8] 2010 15 Bilevel positive airway  
pressure ventilation ST
20.0% Higher respiratory rate, 
higher Apache II score, 
pneumonia, 
comorbidities 
Not  
assessed
Mixed patients
 [8] 2010 7 Bilevel positive airway  
pressure ventilation 
16.9% Higher Apache II score,  
lower Glasgow score,  
lower pH after 1 h NIV
Not as-
sessed
Mixed patients
 [10] 2014 76 Bilevel positive airway  
pressure ventilation ST
60.5% Pneumonia, lower PaCO2 
and HCO3, higher severity 
scores at admission
30% Obese
 [24] 2012 173 Bilevel positive airway  
pressure ventilation 
6.0% Not assessed 6% COPD vs Obese 
patients 
 [25] 2011 44 Bilevel positive airway pressure 
ventilation-ST with AVAPS, 
Pressure control ventilation, PSV
2.0% Not assessed 5% Obese vs  
non-obese
 [26] 2013 30 PSV 38.0% Respiratory rate > 30  
breaths m’, PaO2/FiO2 < 200
pH<7.30
14% Mix patients 
(15% OHS)
 [27] 2016 189 PSV 7.0% Respiratory rate > 30  
breaths m’, PaO2/FiO2 < 200
Not as-
sessed
Mix patients 
(38% OHS)
and enrolled more severe patients: it can 
explain higher NIV failure and mortality rate; 
b)  obese patients who exhibited early NIV failu-
re had a high severity score, more comorbi-
dities and a low HCO3 level at admission and 
were likely to have hypoxemic ARF caused 
by pneumonia [8–10]. Low HCO3 are linked 
to renal failure and more severe illness [10];
c)  factors associated with a successful response 
to NIV included high PaCO2 at admission 
and a diagnosis of idiopathic hypercapnic 
decompensation of OHS [10];
d)  more than half of hypercapnic patients with 
decompensated OHS exhibited a delayed but 
successful response to NIV [8, 10]. The obese 
patients who developed a second episode of 
ARF despite an initial response to NIV (late 
NIV failure) had a poor prognosis [10]. 
In obese patients with ARF neither pH and 
paCO2 accurately predicted patient response to 
NIV in the first hours of NIV treatment [10, 27]. 
The decreased responsiveness in hypoxic and 
hypercapnic ventilatory drive that characterizes 
this last category may explain why they need 
more time than expected to correct respiratory 
acidosis compared to other patients [7, 13]. No 
ventilatory mode has been shown to lead to bet-
ter outcome than any other [28]. Several studies 
demonstrated no differences between pressure 
or volume controlled modes [28]. Several modes 
have been implemented: bilevel positive airway 
pressure [B-PAP], pressure support ventilation 
[PSV], B-PAP-spontaneous-timed [ST] with VAPS 
[volume assured pressure support] and pressure 
controlled ventilation [PCV] [3, 4, 6, 8, 10, 20, 
21, 24–27]. 
The setting of ventilator is very important 
because the high thoracic impedance in these pa-
tients requires higher inspiratory pressure (IPAP) 
levels and expiratory positive airway pressure 
(EPAP) in order to prevent the collapse of the 
upper airway [20] (Fig. 2). 
Delay in the reduction of PaCO2 may be due to: 
1.  Inadequate level of IPAP or EPAP levels: in 
obese patients IPAP should ranged from 12 
to 30 cm H2O or greater and EPAP from 6 to 
8 cm H2O or greater [6, 20]. 
2.  Inadequate duration of NIV: the obese patients 
as previously explained require longer NIV 
therapy than non-obese patients especially 
during the night; their apnea or hypoventila-
tion worsen during hours of sleep [10, 20]. 
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These findings suggest that NIV settings need 
to be monitored more aggressively in OHS ( when 
acute illness precipitates respiratory decompen-
sation ) than in other syndromes [10, 20]. During 
NIV therapy, observation and monitoring of the 
level of consciousness, vital signs, respiratory 
pattern, oxygen saturation and ABG are crucial 
[20, 29, 30]. NIV modality and ventilator setting 
during ARF episode should be adjusted based 
titration with polysomnography [31]. 
Complementary use 
NIV as weaning strategy 
Only few studies address the problem of we-
aning in critically obese patients [32–34]. Currently, 
the management of these patients is based on clinical 
experience and expert opinions [33]. NIV in selected 
chronic hypercapnic patients if applied within the 
first 48 hours post-extubation following established 
weaning protocols reduces hospital mortality. There 
was also a significant reduction of length of ICU 
and hospital stay [33]. This study has shown that 
the use of NIV in the first 48 hours post-extubation 
might be effective in avoiding respiratory failure. 
NIV for obese patients undergoing surgery
Obese patients and particularly those with 
OHS are more likely to develop post-operative re-
spiratory failure, have higher rates of pneumonia, 
and development of atelectasis [21, 35–40]. Both 
upper abdominal and thoracic surgery can result in 
a restriction of pulmonary function that can persist 
for several days due to the reduced ability to clear 
secretions [21]. These problems are often unreco-
gnized. A recent Cochrane review evaluated the 
effectiveness of NIV and CPAP to prevent or to treat 
acute respiratory failure after surgery: it concludes 
that the evidence to support the use of CPAP to redu-
ce pneumonia and re-intubation is not definitively 
demonstrated and further studies are needed [35]. 
We found no study that has delineated risk factors 
for NIV failure in the post-operative period. 
Limitations
This study has some limitations: the paucity 
of studies (always mixed patients do not allow 
us to provide definitive conclusions. Second, 
the proposed ventilation strategies are based on 
expertise of a single center and often derive from 
COPD patients. The use of the type of interface 
(oro-nasal mask or helmet ) as well as side-effects 
or managing problems (leakage, gastric inflation) 
have not been addressed in this review because 
these were not reported in the studies we have 
evaluated. We are aware of their importance in 
the success or failure of any NIV trial. 
Figure 2. NIV setup for obese with ARF
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Conclusion
In conclusion, although few studies are ava-
ilable concerning morbidly obese patients with de-
compensation of OHS, they suggest that NIV could 
be safely used in patients with hypercapnic acute 
respiratory decompensation of OHS. OHS patients 
require more aggressive NIV settings and a longer 
time to reduce PaCO2 levels below 50 mm Hg. 
They frequently exhibit a delayed but success-
ful response to NIV which should encourage 
the pursuit of NIV rather than early intubation. 
Since clear predictors of failure have not been 
identified, a strict and prolonged monitoring is 
mandatory because morbidly obese patients often 
experienced late NIV failure. 
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